Startups
Colospan offers a unique alternative to the diverting stoma by providing a temporary intraluminal bypass which helps reduce the contact of fecal materials with the anastomotic site. This temporary diversion solution is removed without surgery in under two weeks and aims to minimize post-operative complications for a comfortable recovery.
Overview
Location
United States, Massachusetts, Cambridge
Employees
11-50
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 13, 2024 | Colospan Receives FDA Breakthrough Device Designation for Its Intraluminal Bypass Device | CAMBRIDGE, MA, UNITED STATES, August 13, 2024 /EINPresswire.com/ -- Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Device D... |
| May 29, 2024 | Colospan Announces Extended IDE Approval for Its Intraluminal Bypass Device – an Alternative Approach to Diverting Stoma | CAMBRIDGE, MA, UNITED STATES, May 29, 2024 /EINPresswire.com/ -- Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved a product line extensio... |
Reviews 0
FAQ about Colospan Ltd.
What has the press written about Colospan Ltd.?
Parsers VC has collected 3 articles mentioning Colospan Ltd., among them “Colospan Receives FDA Breakthrough Device Designation for Its Intraluminal Bypass Device” (Aug 13, 2024) and “Colospan Announces Extended IDE Approval for Its Intraluminal Bypass Device – an Alternative Approach to Diverting Stoma” (May 29, 2024).
Is Colospan Ltd. still active?
Yes, Colospan Ltd. is active; its latest activity on Parsers VC dates from Jul 5, 2025.